Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT-2 Inhibitors: A Nationwide Population Cohort Study

• Published in: Clinical pharmacology and therapeutics Vol. 115; no. 1; p. 95
• Main Authors: Huang, Shih-Ting, Bair, Pei-Jane, Chang, Shih-Sheng, Kao, Yu-Nong, Chen, San-Ni, Wang, I-Kang, Chiu, Chih-Wei, Chang, Chi-Tzung, Shih, Ying-Hsiu, Li, Chi-Yuan, Yu, Tung-Min
• Format: Journal Article
• Language: English
• Published: United States 01.01.2024
• Subjects: Cohort Studies; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetic Retinopathy - chemically induced; Diabetic Retinopathy - complications; Diabetic Retinopathy - epidemiology; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Humans; Hypoglycemic Agents - adverse effects; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors - adverse effects

Diabetic retinopathy (DR) accounts for 80% of cases of vision loss in patients with type 2 diabetes mellitus (T2DM). Interventional treatments are only indicated in advanced DR and are ineffective in some patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are used to attenuate T2DM-associ...